Patients with the progressive, deadly respiratory ailment known as chronic obstructive pulmonary disease (COPD) have a new COPD drug treatment  to battle the disease, the U.S. Food and Drug Administration said Thursday.The agency approved a new treatment, an inhaled spray called Striverdi Respimat (olodaterol) for COPD drug treatment , the third leading killer of Americans. COPD drug treatment , which is often linked to smoking, involves multiple lung conditions such as chronic bronchitis and emphysema.

Patients with COPD may experience a number of symptoms, such as wheezing, coughing and tightness in their chest. According to the FDA, Striverdi Respimat belongs to a class of medicines known as long-acting beta-adrenergic agonists (LABAs).The agency said the drug works by helping the airway muscles in the lungs stay relaxed, and it can be taken once daily over a prolonged period of time.

Leave a Reply

Your email address will not be published. Required fields are marked *